Gossamer Bio’s Seralutinib Future in Doubt After PROSERA Miss in PAH Raises FDA, Funding and Viability Risks

Gossamer Bio faces significant uncertainty regarding its seralutinib program after the PROSERA trial failed to meet its primary endpoint in pulmonary arterial hypertension (PAH). The FDA may require additional studies, which could delay approval and increase costs. This situation raises concerns about the company's ability to secure funding and maintain the viability of its business. Despite these challenges, the average stock price target for GOSS is $3.69, suggesting a potential upside of 750.03%.